Mp-MRI in the Diagnosis of Liver Fibrosis After Liver Transplantation

March 15, 2022 updated by: The Affiliated Hospital of Qingdao University
It is an open label observation clinical trial, all participants are liver transplant patients. The investigators deem to make a better criteria for assessing liver fibrosis after liver transplantation. The point of the clinical trial is to evaluate the efficacy of multiparameter MRI in the diagnosis of liver fibrosis after liver transplantation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

We collected patients aged 18 to 85 who had undergone liver transplantation. At the same time, all patients underwent liver biopsy or ultrasonic transient elastography after MRI. People who were allergic to gadolinium contrast agent, serious cardiopulmonary disease and contraindications to MRI were excluded.

Study Type

Observational

Enrollment (Anticipated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Guangjie Yang, PhD
  • Phone Number: +86 053282913399
  • Email: ygj_2815@qq.com

Study Locations

  • China
    • Shandong
      • Qingdao, Shandong, China, 266000
        • Recruiting
        • The Affiliated Hospital of Qingdao University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 83 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with liver fibrosis after liver transplantation underwent percutaneous liver biopsy or FibroScan.

Description

Inclusion Criteria:

  • Subjects aged 18 -85 years
  • Patients after liver transplantation
  • Patients who are going to undergo liver biopsy or ultrasonic transient elastography
  • Patients voluntarily joined the study and signed informed consent

Exclusion Criteria:

  • Patients with tumor
  • Patients who are allergic to gadolinium contrast agent
  • Patients with contraindications to magnetic resonance imaging
  • Patients with severe heart and lung diseases
  • Patients who are not suitable for this study according to the researcher's judgment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mp-MRI in the Diagnosis of Liver Fibrosis After Liver Transplantation
Time Frame: 03.18.2022 to12.01.2022
Mp-MRI as a PET-CT biomarker to Liver Fibrosis after Liver Transplantation
03.18.2022 to12.01.2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Affiliated Hospital of Qingdao University

Investigators

  • Study Chair: Guangjie Yang, PhD, The affiliated hostpital of Qingdao University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 18, 2022

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

March 15, 2022

First Submitted That Met QC Criteria

March 15, 2022

First Posted (Actual)

March 23, 2022

Study Record Updates

Last Update Posted (Actual)

March 23, 2022

Last Update Submitted That Met QC Criteria

March 15, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • QYFYWZLL26786

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Fibrosis After Liver Transplantation

Clinical Trials on Gadopentetate Dimeglumine Injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe